These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 10100084

  • 1. Effect of losartan on human platelet activation.
    Guerra-Cuesta JI, Montón M, Rodríguez-Feo JA, Jiménez AM, González-Fernández F, Rico LA, García R, Gómez J, Farré J, Casado S, López-Farré A.
    J Hypertens; 1999 Mar; 17(3):447-52. PubMed ID: 10100084
    [Abstract] [Full Text] [Related]

  • 2. [Effect of losartan on human platelet activation by thromboxane A2].
    Guerra JI, Montón M, Rodríguez-Feo JA, Farré J, Jiménez AM, Núñez A, Gómez J, Rico L, Marcos P, Castilla C, Sánchez De Miguel L, Casado S, López-Farré A.
    Rev Esp Cardiol; 2000 Apr; 53(4):525-30. PubMed ID: 10758030
    [Abstract] [Full Text] [Related]

  • 3. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats.
    Li P, Ferrario CM, Brosnihan KB.
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):198-205. PubMed ID: 9700980
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling.
    Schwemmer M, Sommer O, Bassenge E.
    Cardiovasc Drugs Ther; 2001 Jul; 15(4):301-7. PubMed ID: 11800413
    [Abstract] [Full Text] [Related]

  • 5. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan.
    Núñez A, Gómez J, Zalba LR, Montón M, Jiménez A, Velasco S, López-Blaya A, Uriarte AC, Casado S, López-Farré A.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2):175-9. PubMed ID: 11967810
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin II AT(1) receptor antagonists and platelet activation.
    López-Farré A, Sánchez de Miguel L, Montón M, Jiménez A, Lopez-Bloya A, Gómez J, Núñez A, Rico L, Casado S.
    Nephrol Dial Transplant; 2001 Jun; 16 Suppl 1():45-9. PubMed ID: 11369820
    [Abstract] [Full Text] [Related]

  • 7. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
    Li P, Fukuhara M, Diz DI, Ferrario CM, Brosnihan KB.
    J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Losartan reduces constrictor responses to endothelin-1 and the thromboxane A2 analogue in aortic rings from spontaneously hypertensive rats: role of nitric oxide.
    Maeso R, Rodrigo E, Muñoz-Garcia R, Navarro-Cid J, Ruilope LM, Lahera V, Cachofeiro V.
    J Hypertens; 1997 Dec; 15(12 Pt 2):1677-84. PubMed ID: 9488222
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.
    Jiménez AM, Montón M, García R, Núñez A, Gómez J, Rico L, García-Colis E, de Miguel LS, Arriero MM, Cabestrero F, Farré J, Casado S, López-Farré A.
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):406-12. PubMed ID: 11300653
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
    Yu SM, Wu TS, Teng CM.
    Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
    [Abstract] [Full Text] [Related]

  • 15. Characterization of the inhibition of U46619-mediated human platelet activation by the trimetoquinol isomers. Evidence for endoperoxide/thromboxane A2 receptor blockade.
    Ahn CH, Romstedt KJ, Wallace LJ, Miller DD, Feller DR.
    Biochem Pharmacol; 1988 Aug 01; 37(15):3023-33. PubMed ID: 3134894
    [Abstract] [Full Text] [Related]

  • 16. Differential effects of losartan and candesartan on vasoconstrictor responses in the rat.
    Nossaman BD, Baber SR, Nazim MM, Detrolio JD, Kadowitz PJ.
    Can J Physiol Pharmacol; 2007 Aug 01; 85(3-4):360-71. PubMed ID: 17612645
    [Abstract] [Full Text] [Related]

  • 17. Augmentation of U46619 induced human platelet aggregation by aspirin.
    Kim JM, Koo YK, Jin J, Lee YY, Park S, Yun-Choi HS.
    Platelets; 2009 Mar 01; 20(2):111-9. PubMed ID: 19235053
    [Abstract] [Full Text] [Related]

  • 18. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
    Yin K, Halushka PV, Yan YT, Wong PY.
    J Pharmacol Exp Ther; 1994 Sep 01; 270(3):1192-6. PubMed ID: 7932171
    [Abstract] [Full Text] [Related]

  • 19. Genistein, a protein tyrosine kinase inhibitor, inhibits thromboxane A2-mediated human platelet responses.
    Nakashima S, Koike T, Nozawa Y.
    Mol Pharmacol; 1991 Apr 01; 39(4):475-80. PubMed ID: 2017148
    [Abstract] [Full Text] [Related]

  • 20. Inhibitory effects of resveratrol on platelet activation induced by thromboxane a(2) receptor agonist in human platelets.
    Yang Y, Wang X, Zhang L, An H, Zao Z.
    Am J Chin Med; 2011 Apr 01; 39(1):145-59. PubMed ID: 21213405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.